| Market Capitalization (Millions $) |
174 |
| Shares
Outstanding (Millions) |
6 |
| Employees |
29 |
| Revenues (TTM) (Millions $) |
38 |
| Net Income (TTM) (Millions $) |
-164 |
| Cash Flow (TTM) (Millions $) |
-11 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Cue Biopharma Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, United States. The company is known for its innovative platform technology, called CUE (Control of Unity for Engineered T-Cells), which is designed to harness the body's immune system to fight cancer and other diseases. Cue Biopharma is focused on developing and commercializing therapies that can selectively and specifically target disease-causing cells or tissues, while sparing healthy cells.
The company's primary technology is based on an engineered immune system called Immuno-STATs. Immuno-STATs are a type of molecule that is designed to selectively target and engage immune cells to attack specific disease-causing cells or tissues. This approach has the potential to overcome some of the limitations of traditional immune-based therapies, such as autoimmune reactions in healthy tissue, low response rates, or reduced efficacy over time.
Cue Biopharma's lead product candidate, CUE-101, is a therapeutic, single-chain T cell receptor (sTCR) targeting HPV+ cancers that is being developed for the treatment of head and neck cancer. The company has also developed several other Immuno-STATs, including CUE-102, CUE-103, and CUE-104, which are designed to target other types of cancers, such as melanoma and prostate cancer.
Cue Biopharma's Immuno-STAT platform technology has been validated in several preclinical studies and trials in animals, and the company has received funding and support from several government agencies, including the NIH, the NCI, and the DOD. The company has also entered into collaborations with several leading academic and clinical institutions, including the University of Texas MD Anderson Cancer Center, the Broad Institute of MIT and Harvard, and the Macromoltek Institute.
Cue Biopharma has a highly experienced management team, including President and CEO Daniel Passeri and Chief Medical Officer Ken Pienta, both of whom bring extensive experience in the biopharmaceutical industry. The company is committed to maintaining high ethical standards in all of its operations and has implemented a comprehensive compliance program to ensure that its research and development activities are conducted in accordance with industry best practices and regulatory requirements.
In conclusion, Cue Biopharma is a highly innovative biopharmaceutical company with a strong focus on developing and commercializing therapies that can selectively and specifically target disease-causing cells or tissues, while sparing healthy cells. The company's Immuno-STAT platform technology has the potential to transform the treatment of cancer and other diseases, and its experienced management team and commitment to ethical practices make it a leading player in the biopharmaceutical industry.
Company Address: 40 Guest Street Boston 2135 MA
Company Phone Number: 949-2680 Stock Exchange / Ticker: NASDAQ CUE
|
13.19% 